PD-0806 HDR-BT + SBRT for prostate cancer. QoL and toxicity analysis in a prospective phase II trial.

2021 
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []